CoChat

A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity

Kaur, Manmeet, Misra, Saurav · 2024 · European Journal of Clinical Pharmacology

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Abstract

Background Obesity is one of the critical public health problems in our society. It leads to various health conditions, such as type 2 diabetes mellitus, cardiovascular disease, hypertension, dyslipidaemia, and non-alcoholic fatty liver disease. With the rising incidence of obesity, there is a growing demand for new therapies which can effectively manage body weight and improve health. Current evidence Currently under development, multi-receptor agonist drugs may offer a promising solution to meet this unmet medical need. Retatrutide is a novel triple receptor agonist peptide that targets the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). This novel drug has the potential to treat metabolic abnormalities associated with obesity as well as diseases resulting from it due to its distinct mechanism of action. The Phase III trial of this pipeline drug for treating type 2 diabetes mellitus, non-alcoholic fatty liver disease, and obesity started on August 28, 2023. The results of a Phase II clinical trial have demonstrated significant weight reduction in overweight and obese adults. Specifically, the trial reported an average weight loss of 17.5% and 24.4% at 24 and 48 weeks, respectively. Conclusions These findings hold promise for the development of effective weight loss interventions in this population group. There is a need for more phase III studies to provide sufficient clinical evidence fo…

Overview

Integrity signals

Registry

Crossref · 10.1007/s00228-024-03646-0

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Research works printed but not linked: 2

  1. Purnell JQ (2000) Definitions, Classification, and Epidemiology of Obesity. In: Feingold KR, Anawalt B, Blackman MR et al (eds) Endotext [Internet]. MDText.com, Inc., South Dartmouth (MA). https://www.ncbi.nlm.nih.gov/books/NBK279167/
  2. Chaudharya M, Sharma P (2023) Abdominal obesity in India: analysis of the National Family Health Survey-5 (2019–2021) data. Lancet 14:1–10

Cited by

See all 51

Metadata

Authors
Kaur, M., & Misra, S.
Affiliations
Kalpana Chawla Government Medical College and Hospital (IN)
Corresponding author
Misra, Saurav
Venue
European Journal of Clinical Pharmacology
Published
2024-02-17
Volume
80
Issue
5
Pages
669-676
ISSN
  • 0031-6970 (ISSN-L)
  • 1432-1041
OpenAlex
W4391899493
Cited by
51
References
35
Citations by year
2026: 7 · 2025: 17 · 2024: 27
FWCI
3.18
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • European Journal of Clinical Pharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
retatrutide, obesity, glucagon receptor, glucose-dependent insulinotropic polypeptide receptor, GLP-1 receptor, weight loss, type 2 diabetes, non-alcoholic fatty liver disease, investigational drugs, drug safety and efficacy
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Obesity, Weight Loss, Drugs, Investigational, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. https://app.cochat.ai/papers/10.1007/s00228-024-03646-0
The paper
Kaur, M., & Misra, S. (2024). A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-024-03646-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.